Next Article in Journal
Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
Next Article in Special Issue
Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival
Previous Article in Journal
Integrated Proteogenomic Analysis Reveals Distinct Potentially Actionable Therapeutic Vulnerabilities in Triple-Negative Breast Cancer Subtypes
Previous Article in Special Issue
The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)—What Future Prospects Are There for Its Use in Clinical Practice?
 
 
Article

Article Versions Notes

Cancers 2024, 16(3), 517; https://doi.org/10.3390/cancers16030517
Action Date Notes Link
article xml file uploaded 25 January 2024 08:25 CET Original file -
article xml uploaded. 25 January 2024 08:25 CET Update https://www.mdpi.com/2072-6694/16/3/517/xml
article pdf uploaded. 25 January 2024 08:25 CET Version of Record https://www.mdpi.com/2072-6694/16/3/517/pdf
article supplementary file uploaded. 25 January 2024 08:25 CET - https://www.mdpi.com/2072-6694/16/3/517#supplementary
article html file updated 25 January 2024 08:26 CET Original file -
article html file updated 24 June 2025 09:50 CEST Update -
article html file updated 23 August 2025 03:16 CEST Update https://www.mdpi.com/2072-6694/16/3/517/html
Back to TopTop